Bone marrow cells are routinely accessed clinically for cartilage repair. This study was performed to determine whether adeno-associated virus (AAV) effectively transduces human bone marrow-derived mesenchymal stem cells (hMSC) in vitro, whether AAV infection interferes with hMSC chondrogenesis and whether AAV-transforming growth factor-beta-1 (TGF-b1)-transduced hMSC can improve cartilage repair in vivo. Adult hMSC were transduced with AAVgreen fluorescent protein (GFP) or AAV-transforming growth factor b1 (TGFb1) and studied in pellet cultures. For in vivo studies, AAV-GFP and AAV-TGF-b1-transduced hMSCs were implanted into osteochondral defects of 21 athymic rats. GFP was detected using fluorescent microscopy.
Introduction
Articular cartilage has a unique functional architecture that permits near frictionless joint motion. However, damaged articular cartilage has poor regenerative potential. 1 Chondral and osteochondral injuries are frequently symptomatic, and eventually lead to osteoarthritis, a joint disease reaching epidemic proportions with the aging population. 2, 3 Although the disease is more prevalent in the elderly, it is also a leading cause of disability in the United States. 4 By the year 2030, it is estimated that nearly one-third of all arthritis will occur in working aged adults 45-64. 5 The repair of chondral and osteochondral injuries remain a clinical and scientific challenge. Current clinical treatments of debridement, chondrocyte implantation and marrow stimulation have not been shown to restore consistently a durable articular surface. 6, 7 Osteochondral transplantation is limited by donor site morbidity and the lack of donor tissues. 8 Tissue engineering and gene therapy concepts may improve cartilage repair by introducing repair cells, scaffolds, growth factors and other potential modulators of the osteochondral wound bed. [9] [10] [11] Owing to the limited repair potential of mature differentiated chondrocytes, there has been a strong interest in using mesenchymal stem cells for cartilage tissue engineering. 1, [12] [13] [14] Bone marrow cells are routinely accessed clinically for cartilage repair and form the basis for the repair of osteochondral injuries. [15] [16] [17] The chondrogenic potential of human mesenchymal stem cells (hMSC) is well described. 18, 19 Addition of transforming growth factor-beta-1 (TGF-b1) to hMSC has been shown to consistently induce chondrogenesis while avoiding terminal differentiation [20] [21] [22] [23] [24] Adenoviral mediated transfer of TGF-b1 genes to hMSC has been shown to similarly induce chondrogenesis and inhibit terminal differentiation. 21 Efficient and sustained gene delivery to mesenchymal stem cells with adenovirus, lentivirus and retrovirus have been described. 25 Although viral vectors are effective agents for gene transfer, there are significant safety concerns regarding the use of adenoviruses and retroviruses for clinical gene therapy. Adenovirus is known to induce immunological reactions that can be severe, and even fatal. 26 Retroviral vectors depend on actively proliferating cells for successful transduction, 19 and there are concerns regarding the potential for retrovirus disease transmission and mutagenicity. 27 Lentiviruses are potentially safer than oncoretroviruses in that their replicative cycle occurs independently of cell division. 28 Adeno-associated virus (AAV), a non-pathologic human parvovirus, is also attractive for gene therapy because of its safety profile and its ability to persist in non-dividing cells for extended periods of time. 29, 30 Studies show that AAV can efficiently transduce normal and osteoarthritic human articular cartilage in vitro, 31 as well as rabbit and rat chondrocytes in vivo. 31, 32 AAV may therefore be a suitable vector for gene therapy to improve the cartilage repair potential of hMSC. This study was performed to test the hypotheses that AAV can effectively transduce hMSC in vitro, that transgene expression will be sustained through the processes of in vitro chondrogenesis, and that a novel AAV-TGF-b1 construct can be used to improve osteochondral repair in vivo.
Results

In vitro AAV-GFP
Green fluorescent protein (GFP) transgene expression was observed within 48 h of transfection of hMSC in monolayer culture (Figure 1a ). More than 80% of the hMSC showed GFP expression at 5 days (Figure 1b) . Although continued GFP expression was observed in monolayer culture by fluorescent microscopy throughout the 2-month experiment, GFP intensity appeared to decline with each cell passage.
In three-dimensional pellet culture, fluorescent microscopy showed GFP transgene expression by transfected cells throughout the 21-day study period. Figure 2 demonstrates a typical pellet made from hMSC infected with AAV-GFP vs a control pellet at 14 and 21 days. Control pellets, cultured with hMSC without AAV transduction, showed no GFP fluorescence. Indirect immunofluorescence staining for GFP confirmed transgene expression not only at the surface but also throughout the entire thickness of the pellet at 14 and 21 days (Figure 3 ). Negative control pellet culture sections did not stain for GFP. Histological sections of both transfected and control pellets showed cartilage differentiation evidenced by the presence of chondrocyte-like cells surrounded by proteoglycan-rich matrix showing extensive metachromatic staining with toluidine blue at 14 and 21 days (Figure 3 ).
In vitro AAV-TGF-b1
The supernatant obtained from AAV-TGF-b1-transduced MSC pellet cultures contained greater than 10 ng/ml of TGF-b1 by enzyme-linked immunosorbent assay (ELISA) through the 2-week in vitro study period. TGF-b1 concentrations from AAV-TGF-b1-transduced cultures were at least threefold higher than AAV-GFPtransduced MSC pellet cultures similarly cultured without addition of exogenous TGF-b1 (Po0.0001). Histology of AAV-TGF-b1-transduced pellets showed chondrocyte-like cells surrounded by strong metachromatic staining matrix at 12 weeks consistent with chondrogenic differentiation.
In vivo GFP gene expression
All the three pilot study rats were killed 2 weeks after surgery. Examination using Â 3 loupe magnification showed repair tissue filling the entire defect in both the AAV-GFP defects and the control defects at 2 weeks (Figure 4a and b). When illuminated with 488 nm light, bright green fluorescence was observable with the naked eye within the osteochondral repair area of 3/3 defects filled with AAV-GFP-transduced pellets. When visualized using a Â 2 objective, the green fluorescence was noted to fill the entire defect in the AAV-GFP-transduced pellet (Figure 4c ). Control defects showed no comparable green fluorescence (Figure 4d ).
Six rats per time point were killed at 4, 8 and 12 week time points and the knees receiving AAV-GFP-transduced hMSC pellets were examined using fluorescent microscopy. The percentage of osteochondral defects showing any observable green fluorescence by fluorescent surface imaging was 100% (3/3 rats) at 2, 50% (2/4 rats) at 4, 67% (4/6 rats) at 8, and 17% (1/6 rats) at 12 AAV-transduced human cells improve cartilage repair MR Pagnotto et al weeks. While billing, the implanted pellets were found to be dislodged from the osteochondral defect in two of the 4 week rat knees because of patellar dislocation. These rats were excluded from the analysis. By image analysis, the mean percent areas of the defects that were green were 46, 26, 1.5 and 0.2% for the 2, 4, 8 and 12 week time points, respectively ( Figure 5 ).
In vivo cartilage repair (gross assessment)
A total of six athymic rats per time point were killed at 4, 8 and 12 weeks following implantation of AAV-GFPtransduced hMSC pellets in the right knee (control) and AAV-TGF-b1-transduced pellets in the left knee (experimental). Two 4-week rats were excluded because of patellar dislocation leading to dislodgement of the pellet from the osteochondral defect. In all the remaining knees, gross inspection revealed a smooth appearing repair tissue filling the osteochondral defects. The defect margins remained observable in all knees. There was no synovitis detected in any knees.
In vivo cartilage repair (histological assessment) Table 1 Histological examination 4 weeks after surgery showed a trend towards higher modified Holland scores of 12.572.1 in defects filled with AAV-TGF-b1 compared with 1171.4 in defects filled with AAV-GFP (P ¼ 0.371). 
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Higher Holland scores are indicative of improved defect repair. Repair tissue at 4 weeks was consistently fibrous in both AAV-GFP and AAV-TGF-b1 groups with the exception of one AAV-TGF-b1 rat that showed some spherical chondrocyte-like cells. At the 8-week time point, a continued trend toward improved osteochondral repair was observed in the AAV-TGF-b1 group with an average overall Holland score of 1673.8 compared with 1473.7 for the GFP group (P ¼ 0.237). The AAV-TGF-b1 group showed fibrocartilaginous repairs with greater than 75% spherical chondroid cells within the repair tissues of 4/5 rats. No rats in the AAV-GFP group had fibrocartilage or chondroid cells in any of the repair tissues (0/5). Subchondral bone morphology in the AAV-TGF-b1 group showed regeneration of trabecular and compact bone in 2/5 rats, whereas the AAV-GFP group did not show any trabecular bone in any repairs (0/5). Although 4/5 repairs in the 8-week AAV-TGF-b1 group showed predominantly chondrocyte-like cells, the fifth repair in this group was poor.
At 12 weeks, histological assessment revealed improved cartilage repair with average modified Holland scores of 1474.6 in the GFP-transduced group and 23.771.5 in the TGF-b1-transduced group (P ¼ 0.0047) ( Table 1) . Areas of improved repair tissue within the AAV-TGF-b1 repair included overall defect fill (P ¼ 0.031), more mature subchondral bone morphology (P ¼ 0.014), improved bonding to adjacent bone (P ¼ 0.046), more chondrocyte-like cells within the 'cartilage region of the repair' (P ¼ 0.002), more normal thickness of the neocartilage (P ¼ 0.002) and less degenerative chondrocyte clustering (P ¼ 0.026). All of the GFP repairs healed with fibrous tissue (Figure 6a and b) . All but one of the TGF-b1 group formed either hyaline cartilage or fibrocartilage (defined as spherical morphology observed in X75% of the cells) (Figure 6c and d) . All GFP repairs were thicker than the surrounding cartilage and none of the GFP repairs had normal trabecular bone morphology (Figure 6a and b) . Two of the six TGF-b1 repairs were of similar thickness as the surrounding cartilage and had normal trabecular bone morphology. The remainder of the TGF-b1 repairs had some trabecular bone reformation with recognizable separation of the chondral repair from the subchondral bone (Figure 6c and d) . 
Discussion
These results show that AAV is a suitable vector for gene delivery to improve the in vivo cartilage repair potential of hMSC. AAV-transduced hMSC with high efficiency. In three-dimensional pellet culture, AAV-GFP transfection resulted in sustained GFP expression throughout the 21-day study period. AAV infection did not impede or alter the in vitro chondrogenic potential of the hMSC. Following osteochondral transplantation of AAV-GFPtransduced hMSC, GFP transgene expression was localized to the repair site and persisted in 100% of defects through 2 weeks, during which time early osteochondral repair occurred. A progressive decline in observable GFP occurred over the 12-week in vivo study. Improved cartilage repair tissue was observed in transplanted AAV-TGF-b1-transduced hMSC, 12 weeks after surgery. These findings show that AAV transgene expression persists long enough in vivo to positively influence cartilage repair.
Our results demonstrating localized and sustained in vivo transgene expression in the majority of osteochondral defects through 8 weeks compare favorably with studies using retroviral vectors. Retroviral vectors integrate into the host genome offering theoretical advantages of long-term gene expression that survive cell division. Regional human gene therapy in the form of intra-articular injection of retrovirus-transduced 
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MR Pagnotto et al synovial cells has been shown to result in localized transgene expression when examined 1 week later with no apparent systemic effects. 33 Following genetic labeling of chondrocytes with GFP using a retroviral vector, Mierisch et al. 34 observed a reduction of GFP-labeled chondrocytes from 100% of the initial density to 15% by 4 weeks after implantation into rabbit osteochondral defects. In our study, residual GFP expression was seen through 2 months in monolayer culture and through the 21-day study period in three-dimensional pellet culture. Although diminished, we observed persistent in vivo GFP expression localized to the osteochondral repair site in 4/6 knees through 8 weeks and 1/6 knees through 12 weeks.
Similar to retroviral transfection, AAV transduction effects persist in hMSC through the critical 46 weeks when early osteochondral repair tissue forms.
12,16,35
Clinical rehabilitation following cartilage repair procedures also focus on supporting the repair process during this time frame. Numerous studies using retroviral gene transfer of growth factors such as rhOP-1, rhBMP-2, rhBMP-7 and other cartilage-friendly growth factors have been shown to improve osteochondral repair. [36] [37] [38] [39] We show that AAV transgene expression continues throughout the critical period needed for chondrogenesis of hMSC in vitro, and for modulation of in vivo osteochondral repair. We further demonstrate the feasibility of using AAV-TGF-b1 in an ex vivo gene therapy technique to improve in vivo cartilage repair through delivery of growth factors and human cells to an osteochondral defect.
The technique of ex vivo AAV gene transfer to hMSC followed by in vivo transplantation of the transduced 
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cells offers potential advantages for localized delivery of growth factors to osteochondral defects. Even at early time points, when the in vivo GFP expression was the most robust, we found the GFP expression to be localized to the osteochondral repair site. We have previously shown that sustained release of TGF-b1 following adenoviral vector transduction promoted chondrogenesis of hMSC and inhibited terminal differentiation. 21 The current work demonstrates improved in vivo cartilage repair through implantation of AAV-mediated TGF-b1 gene transfer to hMSC. Although the GFP expression data suggests that TGF-b1 expression is most The table depicts the mean scores from each group for each of the subcategories, and the mean total score for each group. *Mean score differed between GFP and TGF-b1 groups (Pp0.05). The results of this study support the feasibility of using AAV-mediated gene therapy to enhance the cartilage repair potential of hMSC, and show that localized early delivery of TGF-b1 improves cartilage repair. Using gene therapy to achieve safe, localized and sustained in vivo delivery of growth factors to chondrogenic progenitor cells has great potential in the field of cartilage tissue engineering. By genetically enhancing hMSC to overexpress TGF-b1 we were able to show improved cartilage repair of surgically created osteochondral defects. Owing to its recognized safety profile, AAV is currently being used in human clinical trials. 40 These properties support the use of AAV for gene transfer to hMSC as a strategy to improve hMSCmediated articular cartilage repair and regeneration.
Materials and methods
Human bone marrow-derived mesenchymal stem cell culture
Commercially available hMSC and hMSC-growth medium were obtained (Cambrex Bioscience, Walkersville, MD, USA). Cells were isolated and characterized as CD105, CD166, CD29 and CD44 positive, and CD14, CD34 and CD45 negative before purchase. The characterization was independently confirmed at our institution. Cells were expanded in hMSC growth medium until a sufficient number of cells were ready for viral transduction. All experiments were performed with passage 35 cells.
AAV preparation and transduction
Double-stranded serotype two AAV-GFP with a cytomegalovirus promoter (dsAAV2-eGFP heretofore referred to as AAV-GFP) was prepared as previously described and a novel double-stranded serotype 2 AAV-TGF-b1 with a cytomegalovirus promoter (dsAAV2-TGF-b1 heretofore referred to as AAV-TGF-b1) was constructed. 41 A PMAMneo plasmid containing the human TGF-b1 gene under the control of the MMTV-LTR promoter and enhanced by RSVLTR 42 (a gift from Yong Li) was amplified by RT-PCR from human liver cancer cell line HepG2 using forward primer TGF-F: 5 0 -CCATGCCGCCCTCCGGGCTGC-3 0 and reverse primer TGF-R: 5 0 -TCAGCTGCACTTGCAGGAGC-3 0 . The PCR product encoding human TGF-b1 was cloned into the HindIII and NotI sites of plasmid dsAAV-cytomegalovirus-GFP (see reference below) by blunt end ligation. The coding sequence was confirmed by DNA sequencing. The vector was packaged into AAV2 particles, purified and titered using the same methods as described previously. 43 When the hMSC reached 50-80% confluence in T-75 flasks, the cells were infected with AAV-GFP or AAV-TGF-b1 at a concentration of 10 5 virus particles per cell. The transduced hMSC were maintained in hMSC growth medium. To assess the longevity of transgene expression, hMSC infected with AAV-GFP were maintained in monolayer tissue culture by splitting cells 1-4 every 7-10 days for 2 months.
Chondrogenic Pellet Culture with AAV-GFP
Twenty-four to forty-eight hours postinfection in monolayer, GFP expression was confirmed using fluorescent microscopy and cells were transferred from monolayer to chondrogenic pellet culture. The hMSC in monolayer was washed with sterile salt solution, trypsinized, washed again in serum-free medium and counted. The cells were resuspended in chondrogenic medium (CM) (dexamethasone, ascorbate, insulin-transferrin-selenium+premix, penicillin, streptomycin, sodium pyurvate, praline and L-glutamin, with 10 ng/ml TGF-b3 supplemented at the time of use) (Cambrex Bio Science) and separated into aliquots of 250 000 cells in 0.5 ml of CM. The aliquots were then centrifuged at 500 g for 5 min in 15-ml polypropylene conical tubes. The tubes were incubated with loose caps at 371C and 5% CO 2 . Medium was changed every 2-3 days and the tubes were gently flicked to ensure that the pellets were freefloating.
In vitro pellet analysis of AAV-GFP After 14 and 21 days in culture, pellets were examined for GFP expression and chondrogenesis. Pellets were first visualized using fluorescent microscopy for GFP expression. Pellets were then fixed for 1 h in 10% buffered formalin, dehydrated and embedded in paraffin, and cut into sections. Sections were stained with toluidine blue. Indirect immunofluorescence for GFP was also performed.
In vitro pellet analysis of AAV-TGF-b1
Chondrogenic pellet cultures were prepared using cells infected with either AAV-GFP or AAV-TGF-b1 as previously described, except that no exogenous TGF-b1 was added to the cell culture media. Cell culture supernatant of six control AAV-GFP pellets and six experimental AAV-TGF-b1 pellets was collected at 3, 6, 10 and 13 days. Expression of TGF-b1 was assessed by determining the level of TGF-b1 in cell culture supernatant using a commercially available ELISA (R&D Systems, Inc., Minneapolis, MN, USA). Significance was determined using a Student's t-test with Po0.05 considered statistically significant. AAV-TGF-b pellets were prepared for histological analysis as previously described.
In vivo GFP gene expression
All animal surgeries were performed following a University of Pittsburgh Institutional Animal Care and Use Committee approved protocol (protocol No. 0602484). Using a previously described osteochondral defect model, 44 a pilot study was performed with three 3-month-old athymic nude rats. Rats were anesthetized using intraperitoneal injection of pentobarbital. Each knee was prepped with betadine and a midline incision was made over the patella. The skin was retracted, a medial arthrotomy incision was made and the patella was dislocated laterally. The femoral trochlea of each AAV-transduced human cells improve cartilage repair MR Pagnotto et al knee was exposed. A 1.5 Â 1.5 mm defect was created in the midline of the femoral trochlea. Two hMSC pellets were implanted into each defect and held in place using fibrin glue (Baxter Healthcare, Glendale, CA, USA). All pellets were maintained in culture for 2 weeks before implantation. The defect of each right knee was filled with control pellets made with cells that had not been transduced with AAV-GFP and the defect of each left knee was filled with AAV-GFP pellets. Rats were killed 2 weeks after surgery. The knees were examined for GFP expression in situ using fluorescent microscopy to image the articular surface. Image analysis of the surface image was performed to outline the healing defect in each knee.
ImagePro Plus software (Mediacybernetics, Silver Spring, MD, USA) was used to measure the area of GFP fluorescence above background as a percentage of the area defined by the outline of the surgical defect. The knees were then fixed, decalcified, embedded in paraffin and cut into sections for histological evaluation of healing tissue. Sections were stained with hematoxylin and eosin.
In vivo cartilage repair (TGF-b1 vs GFP)
Osteochondral defects were created in the trochlear groove of 18 three-month-old athymic nude rats as described above. In these rats the osteochondral defect of each right knee was filled with two AAV-GFP control pellets, whereas the defect in each left knee was filled with two AAV-TGF-b1 pellets. Six rats were killed at each of the following time points: 4 weeks (n ¼ 6), 8 weeks (n ¼ 6) and 12 weeks (n ¼ 6). Knees were examined for GFP expression in situ using fluorescent microscopy as described in the previous section. The knees were fixed, decalcified, embedded in paraffin and cut into sections for histological evaluation of healing tissue. Sections were stained for haematoxylin and eosin and safranin-O. Histological assessment was performed using a modified osteochondral repair grading scale described by Holland et al. (Table 2) . 45 Mean categorical scoresand total mean scores were analyzed using a Student's t-test with significance level defined as Po0.05. 
